Pelthos Therapeutics Drops 1.35% Amid NYSE Listing

On July 8, 2025, Pelthos Therapeutics experienced a 1.35% drop in pre-market trading, reflecting a slight decline in investor sentiment.

Pelthos Therapeutics, a clinical-stage biotechnology company, has been focusing on developing novel, non-opioid, non-addictive therapeutics to alleviate pain. The company's initial clinical focus is on selectively targeting the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.

Recently, Pelthos Therapeutics announced that it will begin trading on the NYSE American under the ticker symbol 'PTHS' starting July 2, 2025. This move is part of the company's strategic efforts to enhance its market presence and accessibility to a broader range of investors.

Additionally, there have been significant insider activities within the company. Director Richard Malamut was granted 19,108 Restricted Stock Units (RSUs) and 58,230 options at a strike price of $13.50. These equity awards are set to vest over a period of three years, indicating a long-term commitment from the company's leadership.